In this original work, we summarize the current research results of three selected molecules - ABCC3, TRIP6 and CPS1 and their role in resistance to conventionally used chemotherapy - taxanes in ovarian cancer. Selected molecules were studied at in vitro, in vivo level and in tumor tissue samples from ovarian cancer patients. The study also included monitoring the effect of new experimental taxanes, SB-T taxanes, on these molecules. The most interesting was - CPS1 gene, for which we observed a significant expression downregulation in resistant ovarian cancer lines after treatment of new experimental SB-T taxanes with paclitaxel and in in vivo xenograft model of ovarian cancer. Analysis of patient samples showed a relationship between high CPS1 expression with poor patients´ prognosis. Interesting was also the discovery of loss of ABCC3 expression after taxane treatment in ovarian cancer patients.
Šeborová K.; Spálenková A.; Koucká K.; Holý P.; Ehrlichová M.; Wang C.; Ojima I.; Voleska I.; Daniel P.; Balušíková K.; Jelínek M.; Kovář J.; Rob L.; Hruda M.; Mrhalová M.; Souček P.; Václavíková R.: The Role of TRIP6, ABCC3 and CPS1 Expression in Resistance of Ovarian Cancer to Taxanes. Int. J. Mol. Sci.2022, 23(1), 73; doi: 10.3390/ijms23010073.
